Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Date and Time: Wednesday 23 March 2022, 2:00-3:00 pm (UK GMT)

To Join: This is a free event, which will be taking place online via Zoom.

Registration has now closed. Please email HERC@ndph.ox.ac.uk if you would like to details on joining this talk.

ABSTRACT

Standard health valuation methods, such as time trade-off or discrete choice experiments, are inefficient: little information is obtained from each participant. As a result, data from hundreds if not thousands of participants is required to derive health state values (=QALY-weights). 

In this presentation, Paul Schneider (University of Sheffield) will report on the development of the OPUF tool; a new approach for estimating value sets for the EQ-5D-5L, or any other health descriptive system. He will share his experience building the tool, and present findings from a recent UK study, to demonstrate how it can be used to construct value sets on the individual person level.

BIOGRAPHY

Dr. Med. Paul SchneiderPaul Schneider is a PhD student in the Wellcome Trust doctoral training center for public health, economics, and decision science at the School of Health and Related Research (ScHARR), University of Sheffield.

For his PhD, Paul is working on normative issues and empirical methods in the valuation of health.

Paul has a background in clinical medicine and health sciences: He is a physician by training, and completed a doctoral degree in medicine at the Institute for Health Systems Research, University of Witten/Herdecke, Germany. Paul also holds a research masters degree in health sciences from Maastricht University, the Netherlands. Before joining ScHARR in September 2018, he gained experience working on research projects in a range of different areas, including health technology assessment, digital disease surveillance, health service research, clinical drug trials, and global health policy.